Last reviewed · How we verify
BCD-263
BCD-263 is a monoclonal antibody that binds to and inhibits IL-17A, a pro-inflammatory cytokine involved in autoimmune and inflammatory diseases.
BCD-263 is a monoclonal antibody that binds to and inhibits IL-17A, a pro-inflammatory cytokine involved in autoimmune and inflammatory diseases. Used for Psoriasis (plaque psoriasis), Rheumatoid arthritis, Ankylosing spondylitis.
At a glance
| Generic name | BCD-263 |
|---|---|
| Also known as | Nivolumab |
| Sponsor | Biocad |
| Drug class | IL-17A inhibitor (monoclonal antibody) |
| Target | IL-17A |
| Modality | Small molecule |
| Therapeutic area | Immunology / Rheumatology |
| Phase | Phase 3 |
Mechanism of action
IL-17A is a key driver of inflammation in conditions like psoriasis, rheumatoid arthritis, and ankylosing spondylitis. By blocking IL-17A signaling, BCD-263 reduces the recruitment and activation of immune cells at sites of inflammation, thereby suppressing disease activity. This mechanism is distinct from TNF inhibitors and addresses a different arm of the inflammatory cascade.
Approved indications
- Psoriasis (plaque psoriasis)
- Rheumatoid arthritis
- Ankylosing spondylitis
Common side effects
- Nasopharyngitis / upper respiratory tract infection
- Injection site reactions
- Headache
Key clinical trials
- Therapy Adapted for High Risk and Low Risk HIV-Associated Anal Cancer (PHASE2)
- Nivolumab in Treating Patients With Localized Kidney Cancer Undergoing Nephrectomy (PHASE3)
- Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma (PHASE3)
- Brentuximab Vedotin and Nivolumab With or Without Ipilimumab in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma (PHASE1, PHASE2)
- Nivolumab in Treating Patients With Autoimmune Disorders and Advanced, Metastatic, or Unresectable Cancer (PHASE1)
- Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma (PHASE2)
- Testing the Addition of an Anti-cancer Drug, Copanlisib, to the Usual Immunotherapy (Nivolumab With or Without Ipilimumab) in Patients With Advanced Solid Cancers That Have Changes in the Following Genes: PIK3CA and PTEN (PHASE1, PHASE2)
- Adding Nivolumab to Usual Treatment for People With Advanced Stomach or Esophageal Cancer, PARAMUNE Trial (PHASE2, PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- BCD-263 CI brief — competitive landscape report
- BCD-263 updates RSS · CI watch RSS
- Biocad portfolio CI